Scientists say an experimental capsule may trigger fat-burning ketosis in the body using gut bacteria — no bread-ban required
For millions of people who have attempted the ketogenic diet, the promise is irresistible: shed weight rapidly by pushing the body into a fat-burning metabolic state called ketosis. But the reality of keto is far less glamorous. Cutting carbohydrates to near zero — no bread, no pasta, no sweets, no fruit juice — demands a level of discipline that most people simply cannot sustain long-term. Many abandon it within weeks.
Now, a San Diego biotech startup believes it may have found a way to deliver the metabolic payoff of keto without a single dietary sacrifice. The company, Bloom Science, has developed an experimental pill called BL-001 that it says can reprogram the gut microbiome to mimic the physiological effects of the ketogenic diet — triggering fat-burning, appetite suppression, and measurable weight loss — all from a once-daily oral capsule.
It sounds almost too good to be true. But early clinical data, while preliminary, is turning heads in the medical community.
Table of Contents
What is available now?
While BL-001 remains years away from pharmacy shelves, those seeking a proven, accessible weight loss supplement right now need not wait. PhenQ has been one of the most consistently trusted over-the-counter options on the market for over a decade, quietly building a loyal following while prescription-only treatments dominated the headlines.
Unlike injectable GLP-1 drugs or experimental biotherapeutics, PhenQ is available today without a prescription, combining multiple weight loss mechanisms in a single daily pill — including appetite suppression, fat burning, and energy support.
Its multi-action formula, which includes ingredients such as α-Lacys Reset, capsimax powder, and chromium picolinate, is designed to tackle weight loss from several angles simultaneously, making it a practical and popular bridge for people who want results now rather than waiting for the next wave of clinical breakthroughs.
What Is BL-001, and How Does It Work?
BL-001 is classified as a Live Biotherapeutic Product (LBP) — a pharmaceutical-grade preparation of living microorganisms engineered to produce a specific therapeutic effect inside the body. Unlike conventional drugs that work through chemical compounds, BL-001 introduces targeted bacterial strains directly into the gut, where they are designed to shift the microbiome toward a ketogenic metabolic profile.
The ketogenic diet achieves its effects by starving the body of glucose — the sugar derived from carbohydrates — forcing it to break down stored fat into molecules called ketone bodies, which then serve as an alternative fuel source. This metabolic switch, known as ketosis, is associated with weight loss, appetite suppression, steadier energy levels, and — in some clinical populations — a significant reduction in epileptic seizures.
Bloom Science’s hypothesis is that certain gut bacteria play a critical role in mediating these effects, and that by delivering those bacteria directly to the gastrointestinal tract, they can replicate the metabolic pathway without requiring patients to overhaul their diet. Preclinical studies have already demonstrated that BL-001 can reproduce the ketogenic diet’s effect in epilepsy models, as well as modulate GABA (gamma-aminobutyric acid) pathways — a key mechanism for suppressing the neurological hyperexcitability that drives seizures.
The Phase 1 Trial: Promising Early Results
In March 2025, Bloom Science announced the results of its Phase 1 clinical trial — the first formal human study of BL-001. The randomized, double-blind, placebo-controlled trial enrolled 32 adults ranging from healthy weight to overweight. Twenty-four participants received the pill once daily over 28 days, while eight received a placebo. Neither the participants nor the researchers knew who was receiving the active treatment — a gold standard in clinical research design.
The headline results were encouraging. Among overweight participants (those with a BMI of 25 or above), those who received BL-001 achieved a statistically significant placebo-adjusted mean weight loss of 2.3% of their body weight over just four weeks — a result with a p-value of 0.0007, indicating a very low probability the effect was due to chance. The highest individual weight loss recorded in the trial reached 4.9% — nearly five percent of body weight in under a month.
Perhaps even more striking than the weight loss itself was what happened after participants stopped taking the pill. Eighty percent of those who lost weight during the treatment period maintained that weight loss for at least two weeks after their final dose. Even more remarkably, every single overweight participant in the highest dose group continued to lose weight after stopping, ultimately reaching an average total loss of 3.4% by the end of the two-week follow-up.
Beyond the numbers on the scale, analysis confirmed that participants in the BL-001 group experienced measurable ketogenic metabolic changes: elevated urinary ketones — a hallmark of ketosis — as well as reduced appetite and significant shifts in circulating metabolic hormones involved in appetite regulation and digestion. These changes occurred in a dose-dependent manner, meaning higher doses produced stronger effects — a hallmark sign that the drug is biologically active and working as intended.
Critically, no serious adverse events were reported throughout the trial.
A New Phase, and a Bigger Test
Encouraged by the Phase 1 data, Bloom Science has now initiated a Phase 1b trial, dosing its first patient in February 2026. This next stage is larger and longer: 48 adults living with obesity will receive BL-001 or a placebo once daily for 12 weeks — three times longer than the initial study — allowing researchers to assess not only safety and tolerability, but more sustained weight loss outcomes.
The Phase 1b trial is being conducted in Australia and will focus exclusively on individuals classified as obese, rather than the broader range of healthy and overweight adults enrolled in Phase 1. This shift reflects the drug’s intended primary target population and will generate more clinically relevant data for the obesity treatment market.
Dr. Christopher Reyes, biophysicist and CEO of Bloom Science, said the company sees BL-001 as something fundamentally different from existing weight loss drugs. “Millions of patients remain untreated because existing therapies do not align with their preferences,” he said. “BL-001 is designed to change that, delivering the metabolic benefits of the ketogenic diet in a daily oral capsule, without injections or dietary restriction”.
That last point is no small distinction. The two most dominant drugs currently used for obesity — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro, Zepbound) — are injectable GLP-1 receptor agonists, administered via weekly subcutaneous injections. While highly effective, they come with significant side effects for many patients, including nausea, vomiting, and gastrointestinal distress, and they require ongoing use to maintain weight loss. Market research conducted by Bloom Science among several thousand U.S. adults — including a large cohort living with obesity — found strong interest in a ketogenic-metabolic oral alternative, even among those with prior GLP-1 experience.
BL-001 Diet Pill Beyond Obesity: A Potential Lifeline for Epilepsy Patients
One of the more surprising dimensions of BL-001’s development is its potential application in Dravet syndrome — a rare, severe form of genetic epilepsy that typically begins in infancy and causes frequent, prolonged seizures that are notoriously difficult to control with conventional medication.
The ketogenic diet has been used as a therapeutic intervention for drug-resistant epilepsy, including Dravet syndrome, for decades. Clinical evidence shows that the diet can significantly reduce seizure frequency in a meaningful proportion of patients. However, sustaining a strict ketogenic diet in young children is enormously challenging for families, and long-term adherence remains a persistent problem.
Bloom Science believes BL-001 could offer these patients — and their caregivers — a far more manageable alternative. Preclinical studies have already demonstrated the pill’s ability to suppress hyperexcitability in seizure models and modulate GABA pathways, suggesting a real neurological mechanism of action, not merely a metabolic one. The company says it plans to advance BL-001 into Phase 2 trials for both obesity and Dravet syndrome in 2026.
Dr. Louis Licamele, microbiologist and Chief Development Officer at Bloom Science, described the drug as a “groundbreaking approach” to treatment. “We believe BL-001 represents a naturally inspired, multi-pathway solution with the potential to address the limitations of existing therapies,” he said, “providing sustainable weight loss while improving long-term compliance and outcomes”.
Important Caveats of BL-001: Still Early Days
For all the promise BL-001 shows, it is important to place these results in context. Phase 1 trials are primarily designed to assess safety, not efficacy — the participant numbers are small, and the duration of treatment has been brief. A 2.3% mean weight loss over 28 days, while statistically significant and scientifically meaningful, translates to roughly 4–5 lbs for a 200 lb person — modest compared to the dramatic losses often associated with GLP-1 drugs or the keto diet itself over longer periods.
The real test will come in Phase 1b and the Phase 2 trials that follow — larger populations, longer timeframes, and patients with more severe obesity. Researchers will need to determine how much weight patients can realistically lose over three, six, or twelve months, and whether those losses are durable beyond the treatment window.
Bloom Science estimates that BL-001 is still years away from being widely available to the public. Regulatory approval requires successful Phase 2 and Phase 3 trials, a process that typically takes the better part of a decade for a novel therapeutic class.
Still, the science underlying BL-001 is legitimate and distinctive. In a weight-loss drug landscape dominated by injectable GLP-1 agonists and appetite suppressants, a once-daily pill that works by remodeling the gut microbiome to induce ketosis represents a genuinely new direction. If the larger trials confirm what the early data suggests, BL-001 could eventually offer a softer, more accessible on-ramp to the metabolic benefits that keto devotees have long pursued through far more punishing means.
For the approximately 13 million Americans currently following the ketogenic diet — and the many millions more who have tried and failed — that prospect may represent something that has eluded the weight loss industry for generations: a solution that actually fits into real life.
BL-001 is an investigational therapy and has not been approved by the FDA or any regulatory authority. This article is intended for informational purposes only and does not constitute medical advice.
